BT02
Phase 1Small molecule
BT02 is one of 59 small molecule programs targeting Lung Cancer. It is currently in Phase 1.
2
Indications
3
Total Trials
3
Active Trials
58
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
947 competitors in Melanoma
#DrugCompanyPhaseTrials
1Leukine
SanofiPhase 3
Tecentriq
RochePhase 3
Proleukin
IIovance Biotherapeutics, Inc.
Phase 3
Libtayo
RegeneronPhase 3
Imjudo
AstraZenecaPhase 3
Tuoyi
SSun Yat-sen University
Phase 3
Incomplete Freund's Adjuvant
EEastern Cooperative Oncology Group
Phase 3
Deltavit
HHyundai Pharmaceutical Co., LTD.
Phase 3
Epacadostat
IncytePhase 3
Zelboraf
CConrado Roberto Hoffmann Filho
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Relapsed or Refractory Hematologic Malignancies1 trial
Melanoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BT02. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- BBiotroy Therapeutics